Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4755,DB00993,Azathioprine
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4756,DB00993,Azathioprine
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4757,DB00993,Azathioprine
,31094854,Total IFX,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4758,DB00993,Azathioprine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4759,DB00993,Azathioprine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4760,DB00993,Azathioprine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4761,DB00993,Azathioprine
,31094854,antibody,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4762,DB00993,Azathioprine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,15.8,4763,DB00993,Azathioprine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),,12.9,4764,DB00993,Azathioprine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],4.3,4765,DB00993,Azathioprine
,31094854,concentrations,"Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004).",Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094854/),[au] / [ml],6.1,4766,DB00993,Azathioprine
,3957504,half-time of elimination for the first rapid phase (t1/2 alpha),The mean half-time of elimination for the first rapid phase (t1/2 alpha) was 6.1 min (S.D. +/- 4.1) and for the terminal phase (t1/2 beta) 50 min (+/- 31).,Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,6.1,9252,DB00993,Azathioprine
,3957504,terminal phase (t1/2 beta),The mean half-time of elimination for the first rapid phase (t1/2 alpha) was 6.1 min (S.D. +/- 4.1) and for the terminal phase (t1/2 beta) 50 min (+/- 31).,Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,50,9253,DB00993,Azathioprine
,3957504,total plasma clearance (Cl),The total plasma clearance (Cl) was 6.9 1./min (+/- 3.0).,Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),[1] / [min],6.9,9254,DB00993,Azathioprine
,3957504,t1/2 alpha,"The mean t1/2 alpha was 4.6 min (+/- 2.2), t1/2 beta 74 min (+/- 58) and Cl 8.0 1./min (+/- 5.8).",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,4.6,9255,DB00993,Azathioprine
,3957504,t1/2 beta,"The mean t1/2 alpha was 4.6 min (+/- 2.2), t1/2 beta 74 min (+/- 58) and Cl 8.0 1./min (+/- 5.8).",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),min,74,9256,DB00993,Azathioprine
,3957504,Cl,"The mean t1/2 alpha was 4.6 min (+/- 2.2), t1/2 beta 74 min (+/- 58) and Cl 8.0 1./min (+/- 5.8).",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),[1] / [min],8.0,9257,DB00993,Azathioprine
,3957504,minimum effective concentration,"We also studied inhibition of Leucoagglutin (LA) stimulated lymphocyte proliferation by patient plasma at different times in six of the patients following AZA i.v. Sera drawn at 5, 10 and 30 min significantly inhibited the LA-induced proliferation, with an estimated minimum effective concentration of 6-MP in the cultures of about 0.02-0.04 microM.",Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957504/),μM,0.02-0.04,9258,DB00993,Azathioprine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,34.4,16171,DB00993,Azathioprine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,23.4,16172,DB00993,Azathioprine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,17.0,16173,DB00993,Azathioprine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.046,16174,DB00993,Azathioprine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.068,16175,DB00993,Azathioprine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.084,16176,DB00993,Azathioprine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],0.79,16177,DB00993,Azathioprine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.45,16178,DB00993,Azathioprine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.84,16179,DB00993,Azathioprine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],407.6,16180,DB00993,Azathioprine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],251.0,16181,DB00993,Azathioprine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],180.7,16182,DB00993,Azathioprine
,16563975,C0,This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml).,Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563975/),[ng] / [ml],6.6,24661,DB00993,Azathioprine
,14749551,area under the curve (AUC),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],4019,34870,DB00993,Azathioprine
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],3971,34871,DB00993,Azathioprine
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],998,34872,DB00993,Azathioprine
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34873,DB00993,Azathioprine
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34874,DB00993,Azathioprine
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],707,34875,DB00993,Azathioprine
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],734,34876,DB00993,Azathioprine
,2595785,total clearance,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ml] / [h·kg],379,35683,DB00993,Azathioprine
,2595785,volume of distribution,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[l] / [kg],1.4,35684,DB00993,Azathioprine
,2595785,plasma half-life,The mean plasma half-life was 2.7 +/- 1.1 hr.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),h,2.7,35685,DB00993,Azathioprine
,2595785,peak concentration,"When normalized to a 1 mg dose of methylprednisolone, the mean peak concentration at 1 hr was 10.0 +/- 3.5 ng/ml with an 8 hr concentration ranging from 0.3 to 5.5 ng/ml.",Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ng] / [ml],10.0,35686,DB00993,Azathioprine
,3832014,Half-life time,Half-life time of 6-MP formation in blood from AZA at e.g. 37 degrees C was equal to 28.9 +/- 2.8 min.,Kinetics of azathioprine metabolism in fresh human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3832014/),min,28.9,41818,DB00993,Azathioprine
,1837629,trough specific level,"The mean trough specific level was 121 +/- 14 micrograms/L following placebo, compared to 120 +/- 14 micrograms/L during isradipine.",Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1837629/),[μg] / [l],121,50560,DB00993,Azathioprine
,1837629,trough specific level,"The mean trough specific level was 121 +/- 14 micrograms/L following placebo, compared to 120 +/- 14 micrograms/L during isradipine.",Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1837629/),[μg] / [l],120,50561,DB00993,Azathioprine
,16236048,AUC((0-24 h)),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1040,52517,DB00993,Azathioprine
,16236048,C(max),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],109,52518,DB00993,Azathioprine
,16236048,AUC((0-24 h)),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1060,52519,DB00993,Azathioprine
,16236048,C(max),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],107,52520,DB00993,Azathioprine
excess of,9133469,peak CD4 saturations,Ninety-three percent of patients treated at 0.5 mg/kg OKT4A and all patients at higher doses had mean peak CD4 saturations in excess of 90%.,Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9133469/),%,90,60628,DB00993,Azathioprine
,24955449,lev l,"Patients receiving greater than 2.0 mg/kg of azathioprine had greater IFX lev l than those receiving less than 2.0 mg/kg (26.0 vs 10.6 mcg/mL, P = 0.03) and those receiving IFX monotherapy (26.0 vs 11.2 mcg/mL, P = 0.03).","Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24955449/),[mcg] / [ml],26.0,73572,DB00993,Azathioprine
,24955449,lev l,"Patients receiving greater than 2.0 mg/kg of azathioprine had greater IFX lev l than those receiving less than 2.0 mg/kg (26.0 vs 10.6 mcg/mL, P = 0.03) and those receiving IFX monotherapy (26.0 vs 11.2 mcg/mL, P = 0.03).","Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24955449/),[mcg] / [ml],10.6,73573,DB00993,Azathioprine
,24955449,lev l,"Patients receiving greater than 2.0 mg/kg of azathioprine had greater IFX lev l than those receiving less than 2.0 mg/kg (26.0 vs 10.6 mcg/mL, P = 0.03) and those receiving IFX monotherapy (26.0 vs 11.2 mcg/mL, P = 0.03).","Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24955449/),[mcg] / [ml],11.2,73574,DB00993,Azathioprine
,10051048,oral clearance (CL/F),The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[l] / [h·kg],0.21,76612,DB00993,Azathioprine
,10051048,apparent volume of distribution (Vd/F),The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[l] / [kg],2.4,76613,DB00993,Azathioprine
,10051048,half-life,The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),h,8.7,76614,DB00993,Azathioprine
,10051048,accumulation,Tacrolimus accumulation index during chronic therapy (Rac = Cmin(steady state)/Cmin(first dose) normalized to the same dose) averaged 1.3.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),,1.3,76615,DB00993,Azathioprine
,10051048,trough blood levels,Eighty-eight percent of the trough blood levels measured in our patients were within 5 and 20 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],5,76616,DB00993,Azathioprine
,10051048,trough blood levels,Eighty-eight percent of the trough blood levels measured in our patients were within 5 and 20 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],20,76617,DB00993,Azathioprine
,10051048,trough blood concentrations,Pharmacokinetic data suggest that maintenance tacrolimus daily dose should be equal to 0.1 mg/kg/day to obtain trough blood concentrations of approximately 10 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],10,76618,DB00993,Azathioprine
,3898491,clearance,"In the course of CsA treatment, prolongation of half-life was found in most cases, with a significant decrease in clearance (46 +/- 17 L/hr on day 3 versus 28 +/- 10 L/hr on day 15).",Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3898491/),[l] / [h],46,79353,DB00993,Azathioprine
,3898491,clearance,"In the course of CsA treatment, prolongation of half-life was found in most cases, with a significant decrease in clearance (46 +/- 17 L/hr on day 3 versus 28 +/- 10 L/hr on day 15).",Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3898491/),[l] / [h],28,79354,DB00993,Azathioprine
,3898491,terminal half-life,The terminal half-life varied considerably among the patients (24-93 hr) and did not correlate with other pharmacokinetic parameters.,Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3898491/),h,24-93,79355,DB00993,Azathioprine
excess of,9158016,peak CD4 saturations,Ninety-three percent of patients treated at 0.5 mg/kg OKT4A and all patients at higher doses had mean peak CD4 saturations in excess of 90%.,Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158016/),%,90,82201,DB00993,Azathioprine
,2991094,half-life,The half-life of pyridostigmine was between 156 and 210 minutes.,[Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991094/),min,156 and 210,84768,DB00993,Azathioprine
,8085287,plasma IP,"Initial plasma IP level was 2260 ng/ml, whole blood total cyclosporine (T-CsA) concentration was 1,800 ng/ml and that of specific cyclosporine (Sp-CsA), 714 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],714,90235,DB00993,Azathioprine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],232,90236,DB00993,Azathioprine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],401,90237,DB00993,Azathioprine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],96,90238,DB00993,Azathioprine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,43.4,90239,DB00993,Azathioprine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,70.1,90240,DB00993,Azathioprine
,8881811,bioavailabilities,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,7,96426,DB00993,Azathioprine
,8881811,bioavailabilities,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,5,96427,DB00993,Azathioprine
,8881811,bioavailabilities,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,1,96428,DB00993,Azathioprine
,8881811,bioavailability,"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison.","Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881811/),%,47,96429,DB00993,Azathioprine
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],8 and 12,98662,DB00993,Azathioprine
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],15 to 20,98663,DB00993,Azathioprine
,12742493,late loss,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),mm,0.56,98664,DB00993,Azathioprine
,12742493,loss index,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),,0.33,98665,DB00993,Azathioprine
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],869.4,99577,DB00993,Azathioprine
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],211.9,99578,DB00993,Azathioprine
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],1948.8,99579,DB00993,Azathioprine
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],549.4,99580,DB00993,Azathioprine
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],33.3,99581,DB00993,Azathioprine
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],107.9,99582,DB00993,Azathioprine
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],1530.4,99583,DB00993,Azathioprine
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],254.7,99584,DB00993,Azathioprine
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],2615.3,99585,DB00993,Azathioprine
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],841.8,99586,DB00993,Azathioprine
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],21.4,99587,DB00993,Azathioprine
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],61.5,99588,DB00993,Azathioprine
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],8.4 to 129.1,100723,DB00993,Azathioprine
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],41.4,100724,DB00993,Azathioprine
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],37.9 to 172.0,100725,DB00993,Azathioprine
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],91.7,100726,DB00993,Azathioprine
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.7,100727,DB00993,Azathioprine
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.2,100728,DB00993,Azathioprine
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],57.9,105531,DB00993,Azathioprine
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],68.5,105532,DB00993,Azathioprine
,3541320,serum trough radio,The CsA serum trough radioimmunoassay (RIA) was relatively high among hepatotoxic patients with a mean value of 225 +/- 17 ng/ml.,Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3541320/),[ng] / [ml],225,105552,DB00993,Azathioprine
,11007112,AUC,The AUC of 6-MP following administration of AZA into the jejunum (67.0 +/- 30.1 ng x hr/ml) was higher compared to the stomach (39.9 +/- 38.1 ng/hr/ml) and cecum (29.2 +/- 10.9 ng x hr/ml).,Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],67.0,107751,DB00993,Azathioprine
,11007112,AUC,The AUC of 6-MP following administration of AZA into the jejunum (67.0 +/- 30.1 ng x hr/ml) was higher compared to the stomach (39.9 +/- 38.1 ng/hr/ml) and cecum (29.2 +/- 10.9 ng x hr/ml).,Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[ng] / [h·ml],39.9,107752,DB00993,Azathioprine
,11007112,AUC,The AUC of 6-MP following administration of AZA into the jejunum (67.0 +/- 30.1 ng x hr/ml) was higher compared to the stomach (39.9 +/- 38.1 ng/hr/ml) and cecum (29.2 +/- 10.9 ng x hr/ml).,Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],29.2,107753,DB00993,Azathioprine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],16.9,107754,DB00993,Azathioprine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],52.3,107755,DB00993,Azathioprine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],132,107756,DB00993,Azathioprine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],22.2,107757,DB00993,Azathioprine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],63.4,107758,DB00993,Azathioprine
,11007112,AUCs,"The AUCs of AZA following 50, 300, and 600 mg dosages were 16.9 +/- 7.4, 52.3 +/- 67.2, and 132 +/- 151 ng x hr/ml, respectively, and the AUCs of 6-MP were 22.2 +/- 14.9, 63.4 +/- 50.6, and 104 +/- 115 ng x hr/ml, respectively.",Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007112/),[h·ng] / [ml],104,107759,DB00993,Azathioprine
,8616954,elimination half-life (t0.5e),"The washout phase of ATG elimination was analysed over 0-300 days; results were well-fitted by a single exponential decay (r2 > 0.95) giving a mean elimination half-life (t0.5e) of 29.8 days (range 14.3-45.0, n = 9).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),d,29.8,113057,DB00993,Azathioprine
,8616954,apparent volume of distribution of ATG (Vd),"Data for the first 4 days of treatment were analysed with linear regression to obtain a mean value for the apparent volume of distribution of ATG (Vd) of 0.12 l/kg body weight (range 0.07 to 0.17, n = 5).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),[l] / [body·kg·weight],0.12,113058,DB00993,Azathioprine
,43222,terminal half-life,"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),min,41.6,114775,DB00993,Azathioprine
,43222,plasma clearance (CLp),"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),[ml] / [kg·min],48.4,114776,DB00993,Azathioprine
,43222,volume of distribution (Vdss),"Following iv 6-MP administration, 6-MP levels were described by a two-compartment body model; mean terminal half-life; plasma clearance (CLp), and volume of distribution (Vdss) were 41.6 +/- 12.1 min, 48.4 +/- 15.4 ml/min/kg, and 1.76 +/- 0.64 liters/kg, respectively.",Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the rhesus monkey. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43222/),[l] / [kg],1.76,114777,DB00993,Azathioprine
,12962871,Cmax,A Cmax (30.5+/-13.8 ng/mL) was reached at 2.3+/-1.5 h.,Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],30.5,118331,DB00993,Azathioprine
,12962871,trough levels,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],10-20,118332,DB00993,Azathioprine
,12962871,exposure,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[h·ng] / [ml],230.6,118333,DB00993,Azathioprine
,9884251,duration of,"The median duration of the initial episode of i.v. cyclosporine was 4.0 days for Neoral, compared to 6.5 days for Sandimmun (P<0.001).",Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884251/),d,4.0,126663,DB00993,Azathioprine
,9884251,duration of,"The median duration of the initial episode of i.v. cyclosporine was 4.0 days for Neoral, compared to 6.5 days for Sandimmun (P<0.001).",Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884251/),d,6.5,126664,DB00993,Azathioprine
,9048271,relative bioavailabilities,"The relative bioavailabilities of 6-mercaptopurine after ileocolonic azathioprine administration via delayed-release oral capsules at doses of 200 mg, 400 mg, and 600 mg (means of 15%, 15%, and 12%, respectively) were all significantly less than 100% compared with standard oral azathioprine at a 100-mg dose.",A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048271/),%,15,141789,DB00993,Azathioprine
,9048271,relative bioavailabilities,"The relative bioavailabilities of 6-mercaptopurine after ileocolonic azathioprine administration via delayed-release oral capsules at doses of 200 mg, 400 mg, and 600 mg (means of 15%, 15%, and 12%, respectively) were all significantly less than 100% compared with standard oral azathioprine at a 100-mg dose.",A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048271/),%,12,141790,DB00993,Azathioprine
less,9048271,relative bioavailabilities,"The relative bioavailabilities of 6-mercaptopurine after ileocolonic azathioprine administration via delayed-release oral capsules at doses of 200 mg, 400 mg, and 600 mg (means of 15%, 15%, and 12%, respectively) were all significantly less than 100% compared with standard oral azathioprine at a 100-mg dose.",A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9048271/),%,100,141791,DB00993,Azathioprine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],0.25,143668,DB00993,Azathioprine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],1.35,143669,DB00993,Azathioprine
,15795639,Oral clearance (CL/F),Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h).,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],22.1,143670,DB00993,Azathioprine
,15795639,relative oral bioavailability,The relative oral bioavailability of Sandimmune to Neoral was 0.82.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),,0.82,143671,DB00993,Azathioprine
,26265043,AUC0-24h,"The AUC0-24h was 195.5 h/nmol/l, the terminal elimination half-life was 10.2 h, and the kel was 0.068 h(-1).","Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26265043/),[h] / [l·nM],195.5,147881,DB00993,Azathioprine
,26265043,terminal elimination half-life,"The AUC0-24h was 195.5 h/nmol/l, the terminal elimination half-life was 10.2 h, and the kel was 0.068 h(-1).","Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26265043/),h,10.2,147882,DB00993,Azathioprine
,26265043,kel,"The AUC0-24h was 195.5 h/nmol/l, the terminal elimination half-life was 10.2 h, and the kel was 0.068 h(-1).","Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26265043/),1/[h],0.068,147883,DB00993,Azathioprine
,16386613,trough level (C(0)),"Mean CsA trough level (C(0)) measured at first week posttransplant was significantly lower in the rejection than the no-rejection group (125.17 +/- 56.9 ng/mL versus 169.33 +/- 48.27 ng/mL, P = .001).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],125.17,148675,DB00993,Azathioprine
,16386613,trough level (C(0)),"Mean CsA trough level (C(0)) measured at first week posttransplant was significantly lower in the rejection than the no-rejection group (125.17 +/- 56.9 ng/mL versus 169.33 +/- 48.27 ng/mL, P = .001).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],169.33,148676,DB00993,Azathioprine
,16386613,C(0),ROC analysis showed that C(0) of 150 ng/mL provided the optimal cutoff.,Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148677,DB00993,Azathioprine
>,16386613,C(0),"Patients with mean C(0) >150 ng/mL over the first week had less incidence of acute rejection than patients with levels <150 ng/mL (30.3% versus 64.9%) (P = .009, Cochran-Mantel-Haenszel test).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148678,DB00993,Azathioprine
above,16386613,early trough levels,"In conclusion, our data suggest that in heart transplant patients it may be crucial to target early trough levels above 150 ng/mL during the first days postsurgery to avoid rejection.",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148679,DB00993,Azathioprine
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],5.2,149623,DB00993,Azathioprine
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],9.4,149624,DB00993,Azathioprine
<,14550821,trough levels,"We observed a significantly increased risk of acute rejection at everolimus trough levels <3 ng/ml, which constitutes the lower therapeutic concentration limit when everolimus is used with conventionally dosed cyclosporine.","Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],3,149625,DB00993,Azathioprine
,14550821,troughs,Everolimus-related adverse events were manageable up to the highest troughs (22 ng/ml) observed in this population.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],22,149626,DB00993,Azathioprine
,2595781,total-body clearance,"Mean +/- SE total-body clearance and elimination half-life were 887 +/- 159 ml/min and 1.4 +/- 0.2 hr, respectively, in the i.v. bolus study, indicating that 6-MP is rapidly cleared from the systemic circulation.",The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595781/),[ml] / [min],887,152842,DB00993,Azathioprine
,2595781,elimination half-life,"Mean +/- SE total-body clearance and elimination half-life were 887 +/- 159 ml/min and 1.4 +/- 0.2 hr, respectively, in the i.v. bolus study, indicating that 6-MP is rapidly cleared from the systemic circulation.",The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595781/),h,1.4,152843,DB00993,Azathioprine
,8160249,maximal 6-MP plasma concentration (Cmax),"Mean maximal 6-MP plasma concentration (Cmax) was 340 nmol/L (SD = 290), mean time to Cmax (Tmax) was 2 h (SD = 1.8), and mean area under the plasma concentration-time curve (AUC) was 930 nmol/L/h (SD = 770).",Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[nM] / [l],340,152933,DB00993,Azathioprine
,8160249,time to Cmax (Tmax),"Mean maximal 6-MP plasma concentration (Cmax) was 340 nmol/L (SD = 290), mean time to Cmax (Tmax) was 2 h (SD = 1.8), and mean area under the plasma concentration-time curve (AUC) was 930 nmol/L/h (SD = 770).",Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),h,2,152934,DB00993,Azathioprine
,8160249,area under the plasma concentration-time curve (AUC),"Mean maximal 6-MP plasma concentration (Cmax) was 340 nmol/L (SD = 290), mean time to Cmax (Tmax) was 2 h (SD = 1.8), and mean area under the plasma concentration-time curve (AUC) was 930 nmol/L/h (SD = 770).",Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[nM] / [h·l],930,152935,DB00993,Azathioprine
,8160249,fraction,The mean fraction of azathioprine dose excreted as 6-MP in urine was 1.32% (SD = 1.11).,Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),%,1.32,152936,DB00993,Azathioprine
,8160249,maxima,In this group of patients the observed 6-TGN levels in RBCs were low; maxima during the observation period ranged from undetectable to 250 pmol/8 x 10(8) RBCs.,Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[pM] / [8],und,152937,DB00993,Azathioprine
,8160249,maxima,In this group of patients the observed 6-TGN levels in RBCs were low; maxima during the observation period ranged from undetectable to 250 pmol/8 x 10(8) RBCs.,Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8160249/),[pM] / [8],250,152938,DB00993,Azathioprine
,9263380,blood/ plasma ratio,Blood and plasma sirolimus concentrations were analyzed by an electrospray-high performance liquid/mass spectrophotometric (ESP-HPLC/MS) method Sirolimus showed an extensive red blood cell distribution with a mean blood/ plasma ratio of 49.1.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),,49.1,160379,DB00993,Azathioprine
,9263380,elimination half-life,The elimination half-life ranged from 43.8 to 86.5 hours (mean 56.9 hours).,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),h,56.9,160380,DB00993,Azathioprine
,9263380,oral dose clearance,The oral dose clearance ranged from 42 to 339 ml/h.kg.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),[ml] / [h·kg],42 to 339,160381,DB00993,Azathioprine
,8366177,steady-state concentrations,"The steady-state concentrations of AZN observed in these patients ranged from 6 to 583 micrograms/L, and the interday coefficients of variation of the concentration in three randomly selected patients were 38%, 12%, and 4.6%.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[μg] / [l],6 to 583,164031,DB00993,Azathioprine
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],0.126 to 4,164032,DB00993,Azathioprine
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],5 to 12,164033,DB00993,Azathioprine
,8366177,alpha,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),1/[h],15.3,164034,DB00993,Azathioprine
,8366177,total body clearance,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],8.12,164035,DB00993,Azathioprine
,1002367,Elimination,"Elimination during eight hours of haemodialysis amounted to 45%, which is only slightly less than the elimination in the urine of normal persons over a period of 24 hours.",Pharmacokinetics of azathioprine under haemodialysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1002367/),%,45,166071,DB00993,Azathioprine
,16261832,elimination half-life,"Plasma concentrations of AZA and its metabolite, 6-MP decreased rapidly from plasma following i.v. administration of AZA, consistent with the short mean elimination half-life of 1.8 minutes.",Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261832/),min,1.8,167208,DB00993,Azathioprine
,16261832,Oral bioavailability,"Oral bioavailability of AZA was low, ranging from 1% to 7%.",Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261832/),%,1,167209,DB00993,Azathioprine
,16261832,Oral bioavailability,"Oral bioavailability of AZA was low, ranging from 1% to 7%.",Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16261832/),%,7,167210,DB00993,Azathioprine
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176633,DB00993,Azathioprine
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.12,176634,DB00993,Azathioprine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.13,176635,DB00993,Azathioprine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176636,DB00993,Azathioprine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176637,DB00993,Azathioprine
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.18,176638,DB00993,Azathioprine
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176639,DB00993,Azathioprine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176640,DB00993,Azathioprine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.10,176641,DB00993,Azathioprine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176642,DB00993,Azathioprine
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],405,181655,DB00993,Azathioprine
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],373,181656,DB00993,Azathioprine
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.5,181657,DB00993,Azathioprine
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.3,181658,DB00993,Azathioprine
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.7,181659,DB00993,Azathioprine
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.6,181660,DB00993,Azathioprine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1419.1,186526,DB00993,Azathioprine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1460.5,186527,DB00993,Azathioprine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],129,186528,DB00993,Azathioprine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1342,186529,DB00993,Azathioprine
,40585,plasma half-life,"In a kidney transplant patient given azathioprine, 50 mg i.v., conversion to 6-MP was rapid and the plasma half-life of 6-MP was 36 min.","Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/40585/),min,36,193707,DB00993,Azathioprine
,2526020,peak plasma 6-TU concentration,A peak plasma 6-TU concentration of 710.7 ng/ml was observed at 3.8 h after oral dosing.,Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2526020/),[ng] / [ml],710.7,194659,DB00993,Azathioprine
,2526020,peak concentration,6-MP plasma concentrations in the patients were low (mean peak concentration 36.0 ng/ml) and rapidly disappeared within 8 h.,Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2526020/),[ng] / [ml],36.0,194660,DB00993,Azathioprine
,9428817,serum half-life,"The serum half-life of daclizumab was 20 days, and its administration resulted in prolonged saturation of interleukin-2alpha receptors on circulating lymphocytes.",Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428817/),d,20,198235,DB00993,Azathioprine
,9877312,area under the plasma concentration-time curve (AUC),The mean observed area under the plasma concentration-time curve (AUC) was 190+/-140 ng mL(-1) h and the elimination rate constant (Kel) was 1.92+/-1.,6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877312/),[h·ng] / [ml],190,204144,DB00993,Azathioprine
,9877312,elimination rate constant (Kel),The mean observed area under the plasma concentration-time curve (AUC) was 190+/-140 ng mL(-1) h and the elimination rate constant (Kel) was 1.92+/-1.,6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9877312/),,1.92,204145,DB00993,Azathioprine
,2396307,detection limit,The detection limit was 6 nM.,Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396307/),nM,6,207226,DB00993,Azathioprine
,2396307,detection limit,A Beckman ODS column was used and the detection limit was 5 nM.,Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396307/),nM,5,207227,DB00993,Azathioprine
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00993,Azathioprine
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00993,Azathioprine
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00993,Azathioprine
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00993,Azathioprine
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00993,Azathioprine
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00993,Azathioprine
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00993,Azathioprine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00993,Azathioprine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00993,Azathioprine
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00993,Azathioprine
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00993,Azathioprine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00993,Azathioprine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00993,Azathioprine
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00993,Azathioprine
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),[μg] / [h·ml],52.68,215239,DB00993,Azathioprine
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),,4,215240,DB00993,Azathioprine
,21323897,AUC,The median AUC per mg 6-TG was 1068 (p.o.) and 7184 (i.v.) pmol·h (8 × 10(8) RBC)(-1) .,Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323897/),(·h·pM,1068,217132,DB00993,Azathioprine
,21323897,AUC,The median AUC per mg 6-TG was 1068 (p.o.) and 7184 (i.v.) pmol·h (8 × 10(8) RBC)(-1) .,Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21323897/),(·h·pM,7184,217133,DB00993,Azathioprine
,30169593,elimination half-life,"All patients discontinuing thiopurines displayed first-order elimination kinetics of 6-TGN, with a median elimination half-life of 6.8 days [interquartile range 5.9-8.4].",Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169593/),d,6.8,221293,DB00993,Azathioprine
less,30169593,elimination half-life,"Upon 6MP/azathioprine discontinuation, a 6-TGN elimination half-life of less than 10 days is expected in most patients.",Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169593/),d,10,221294,DB00993,Azathioprine
,17038879,Tmax,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),h,1.9,221311,DB00993,Azathioprine
,17038879,Tmax,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),h,1.5,221312,DB00993,Azathioprine
,17038879,C2,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),[ng] / [ml],988,221313,DB00993,Azathioprine
,17038879,C2,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),[ng] / [ml],720,221314,DB00993,Azathioprine
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],5.2,222537,DB00993,Azathioprine
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],9.4,222538,DB00993,Azathioprine
> or =,15575918,trough levels,Biopsy-proven acute rejection (BPAR) was reduced with everolimus trough levels > or =3 ng/mL.,Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],3,222539,DB00993,Azathioprine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],384.2,223848,DB00993,Azathioprine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],392.0,223849,DB00993,Azathioprine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223850,DB00993,Azathioprine
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],96.0,223851,DB00993,Azathioprine
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],98.0,223852,DB00993,Azathioprine
,12395976,Cmax,"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223853,DB00993,Azathioprine
,12395976,C(max-DN10mg),These values were 7-8 times higher than the normalized value of C(max-DN10mg) for the control group (13.7 ng/ml).,Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],13.7,223854,DB00993,Azathioprine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1228.2,223855,DB00993,Azathioprine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1214.1,223856,DB00993,Azathioprine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],345.9,223857,DB00993,Azathioprine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],157.5,223858,DB00993,Azathioprine
,8351718,initial steady state concentrations,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],400,227612,DB00993,Azathioprine
,8351718,AUC divided by dosing interval,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],550,227613,DB00993,Azathioprine
,8351718,trough levels,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],200,227614,DB00993,Azathioprine
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],29,239826,DB00993,Azathioprine
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],18,239827,DB00993,Azathioprine
,11264639,clearance,Both were significantly lower compared with a clearance of 37+/-15 mL/h from a previous study of basiliximab with dual therapy (p<0.001).,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],37,239828,DB00993,Azathioprine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239829,DB00993,Azathioprine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239830,DB00993,Azathioprine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239831,DB00993,Azathioprine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239832,DB00993,Azathioprine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239833,DB00993,Azathioprine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239834,DB00993,Azathioprine
,12595513,trough,Lowering CsA to low target CsA trough (30 to 70 ng/ml) never led to acute rejection or major renal function deterioration.,Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12595513/),[ng] / [ml],30 to 70,240980,DB00993,Azathioprine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,96,248802,DB00993,Azathioprine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,97,248803,DB00993,Azathioprine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,90,248804,DB00993,Azathioprine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,83,248805,DB00993,Azathioprine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,74,248806,DB00993,Azathioprine
,30784100,drug retention rates,"The drug retention rates were similar for optimised monotherapy and combination treatment after induction (96% vs 97%, P = 0.73), after the first year (90% vs 83%, P = 0.23) and at the end of follow-up (74% vs 75%, P = 0.968).","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),%,75,248807,DB00993,Azathioprine
,30784100,trough levels,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),[μg] / [ml],1.7,248808,DB00993,Azathioprine
,30784100,trough levels,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),[μg] / [ml],5.0,248809,DB00993,Azathioprine
,30784100,drug-to-trough ratio,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),,3.9,248810,DB00993,Azathioprine
,30784100,drug-to-trough ratio,"Higher infliximab consumption (7.6 mg/kg q8 weeks [interquartile range (IQR): 5.9-10.3] vs 6.4 mg/kg q8 weeks [IQR: 5.2-8.0], P = 0.019) combined with lower trough levels (1.7 µg/mL [IQR: 0.3-6.6] vs 5.0 µg/mL [2.5-8.7], P = 0.012) resulted in almost 3-fold higher drug-to-trough ratio (3.9 vs 1.5) in monotherapy compared to combination strategy at year 1.","Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30784100/),,1.5,248811,DB00993,Azathioprine
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],449,249174,DB00993,Azathioprine
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],428,249175,DB00993,Azathioprine
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],32,249176,DB00993,Azathioprine
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],30,249177,DB00993,Azathioprine
,9422405,terminal half-life,Postinfusion concentrations declined in a biphasic manner with a terminal half-life of 6.5+/-2.1 days.,"Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422405/),d,6.5,249622,DB00993,Azathioprine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),[mg] / [l],0.09 to 1.16,251320,DB00993,Azathioprine
,33150655,steady-state trough concentrations,"Using high-performance liquid chromatography, we measured 156 steady-state trough concentrations of 6-TGN within the range 0.09 to 1.16 mg/L (ie 133-1733 pmol per 8 × 108 RBC).",Population pharmacokinetics of azathioprine active metabolite in patients with inflammatory bowel disease and dosage regimens optimisation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33150655/),pM,133-1733,251321,DB00993,Azathioprine
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],3.88,252560,DB00993,Azathioprine
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.54,252561,DB00993,Azathioprine
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.94,252562,DB00993,Azathioprine
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2040,252563,DB00993,Azathioprine
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2757,252564,DB00993,Azathioprine
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],3297,252565,DB00993,Azathioprine
,2341582,peak plasma 6-MP level,The low peak plasma 6-MP level of 73.7 +/- 23.7 ng/mL (mean +/- SD) and the short half-life (t1/2) of 1.9 +/- 0.6 hours suggest rapid conversion of 6-MP to other metabolites.,"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341582/),[ng] / [ml],73.7,252728,DB00993,Azathioprine
,2341582,half-life (t1/2),The low peak plasma 6-MP level of 73.7 +/- 23.7 ng/mL (mean +/- SD) and the short half-life (t1/2) of 1.9 +/- 0.6 hours suggest rapid conversion of 6-MP to other metabolites.,"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341582/),h,1.9,252729,DB00993,Azathioprine
,2341582,peak plasma 6-TU concentration,A peak plasma 6-TU concentration of 1210 +/- 785 ng/mL was observed at 3.5 +/- 0.6 hours after the AZA dose.,"Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341582/),[ng] / [ml],1210,252730,DB00993,Azathioprine
,16573602,C0,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],96.2,259396,DB00993,Azathioprine
,16573602,C2,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],504,259397,DB00993,Azathioprine
,9776421,Elimination half-life,Elimination half-life was longer in the 9 cyclosporine-treated subjects (108.0+/-13.6 min) than in the other nine (71.2+/-8.3 min; p <0.02).,Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776421/),min,108.0,262698,DB00993,Azathioprine
,9776421,Elimination half-life,Elimination half-life was longer in the 9 cyclosporine-treated subjects (108.0+/-13.6 min) than in the other nine (71.2+/-8.3 min; p <0.02).,Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776421/),min,71.2,262699,DB00993,Azathioprine
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00993,Azathioprine
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00993,Azathioprine
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00993,Azathioprine
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00993,Azathioprine
,8852717,C.V.,"The limit of quantification was at 2.5 +/- 0.256 ng (C.V. 10.25%), thus allowing drug monitoring in long-term patients.",High-performance liquid chromatographic assay for the measurement of azathioprine in human serum samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852717/),%,10.25,271894,DB00993,Azathioprine
